Abbvie Inc.

Abbott Laboratories Corporation

Eric C Breinlinger

Michael M Friedman

Maria A Argiriadi

Noel S Wilson

Justin D Dietrich

Augustine Osuma

Anil Vasudevan

Kristine E Frank

Adrian Hobson

Kelly Mullen

Kevin Patrick Cusack

David Ihle

Kenton L Longenecker

David J Calderwood

Martine Barth

Michael Morytko

Dawn M George

Andrew Burchat

Graham K Ansell

Phil B Cox

David Andrew Kinsman

Shannon R Fix-Stenzel

Pintipa Grongsaard

Dominique Potin

Ann Marie Rowley

Huan-Qui Li

Shuhui Chen

Stevan Wakefield Djuric

Marlon D Cowart

Anna M Ericsson

Arthur Gomtsyan

Michael R Schrimpf

Jerome F Daanen

Michael E Kort

Kevin R Woller

Thomas D Gordon

Wentao Wu

Huaqing Liu

Robert G Schmidt

Marc J Scanio

Michael Z Hoemann

Neil Wishart

Jianfei Wang

Jeffrey W Voss

Biqin C Li

Lu Wang

Subhendu Mukherjee

Grier A Wallace

Dominique Bonafoux

Didier Thomas

Nathan Josephsohn

Gagandeep K Somal

Fabrice Guillier

Martin E Hayes

J Martin Herold

Eric R Goedken

Jerome Amaudrut

Stacy A Van Epps

Matthew H Katcher

Steven L Swann

Linlin Dai

Jérôme Amaudrut

Ellen Yulin Tsai Chien

David J Hardee

Wei Qiu

Thomas R Vargo

Matthew P Webster

Robert H Stoffel

Andrew J Little

Amanda W Dombrowski

Gloria Y LoSchiavo

Siva Sanjeeva Rao Thunuguntla

Subramanya Seetharama Shastry Hosahalli

Venkata Srikanth Chitty

Olivia Poupardin

Laurent Mounier

Jeremy Edmunds

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

Indazolones as modulators of TNF signaling

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

Indazolones as modulators of tnf signaling

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Nuclear receptor modulators

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof

The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.

Isoxazolines as therapeutic agents

The invention provides a compound of Formula (Ie), 

Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family.

Sphingosine-1-phosphate receptor agonist and antagonist compounds

Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

Oxadiazole compounds

Growing community of inventors

Charlton, MA, United States of America

Eric C Breinlinger